TrialJapanese journal of ophthalmology2023

Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.

Masahiko Shimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.